Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immuron, Ltd. (NASDAQ: IMRN).

Full DD Report for IMRN

You must become a subscriber to view this report.

Recent News from (NASDAQ: IMRN)

US Department of Defense Reports Travelan Protects Against Shigella in Primates
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated NHPs compared to placebo. A preventative ...
Source: GlobeNewswire
Date: September, 05 2018 10:00
Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate
Biohaven launches Phase 2/3 study of trigriluzole in Alzheimer's Discussion : Biohaven Pharmaceutical Holding Company ( BHVN ) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expec...
Source: SeekingAlpha
Date: July, 27 2018 03:48
Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
Key Highlights: Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17. US Travelan® sales continue to exceed expectations growing to AU$765k which represents a 114% increase over ...
Source: GlobeNewswire
Date: July, 25 2018 10:00
Immuron Announces it has Received a European Patent Grant for NASH treatment
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infe...
Source: GlobeNewswire
Date: July, 24 2018 06:29
US Department of Defense Research Collaboration Moves Forward
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completed Studies commissioned by the US Department of Defense to evaluate Travelan®’s ability to neutralise pathogenic bacteria of interest, including   &#...
Source: GlobeNewswire
Date: July, 24 2018 06:28


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMRN.

About Immuron, Ltd. (NASDAQ: IMRN)

Logo for Immuron, Ltd. (NASDAQ: IMRN)

Immuron Ltd ASX: IMC OTCQB: IMROY is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan for the prevention of Travelers diarrhea, whilst its lead product candidate IMM E is in Phase b clinical trials for NASH and ASH. These products together with the Company s other preclinical immunotherapy pipeline products targeting immune related diseases currently under development, will meet a large unmet need in the market.


Contact Information



Current Management

  • Dr.Jerry Kanellos / COO, Chief Scientific Officer
  • Peter Vaughan / CFO, Secretary
  • Phillip Allen Hains / CFO, Secretary
  • Dr. Dan Peres / Senior VP, SVP, Product Dev.
  • Agapitos Elefterios Peter Anastasiou / Executive Vice Chairman
  • Dr. Roger Aston / Director
  • Daniel Jude Pollock / Director
  • Stephen Anastasiou / NonExecutive Director

Current Share Structure

  • Market Cap: $22,561,309 - 05/16/2018
  • Issue and Outstanding: 105,641,417 - 03/02/2017


Daily Technical Chart for (NASDAQ: IMRN)

Daily Technical Chart for (NASDAQ: IMRN)

Stay tuned for daily updates and more on (NASDAQ: IMRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMRN)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMRN and does not buy, sell, or trade any shares of IMRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: